Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jules Leonard Dienstag, M.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. N01DK92319-17-0-1 (DIENSTAG, JULES L) May 1, 1999 - Apr 30, 2010
    NIH/NIDDK
    Hepatitis C Clinical Trial-Clinical Center
    Role: Principal Investigator
  2. N01DK092319 (DIENSTAG, JULES LEONARD) May 1, 1999 - Apr 30, 2007
    NIH/NIDDK
    HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS
    Role: Principal Investigator
  3. M01RR001066 (SLAVIN, PETER L) Dec 1, 1997 - Nov 30, 2007
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Krupat E, Dienstag JL, Padrino SL, Mayer JE, Shore MF, Young A, Chaudhry HJ, Pelletier SR, Reis BY. Do Professionalism Lapses in Medical School Predict Problems in Residency and Clinical Practice? Acad Med. 2020 Jun; 95(6):888-895. PMID: 31895703.
    Citations:    
  2. Luther J, Khan S, Gala MK, Kedrin D, Sridharan G, Goodman RP, Garber JJ, Masia R, Diagacomo E, Adams D, King KR, Piaker S, Reinecker HC, Yarmush ML, Argemi J, Bataller R, Dienstag JL, Chung RT, Patel SJ. Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proc Natl Acad Sci U S A. 2020 May 26; 117(21):11667-11673. PMID: 32393626.
    Citations:    
  3. Dienstag JL. Kurt J. Isselbacher, M.D., Remembered (1925-2019). Hepatology. 2020 Mar; 71(3):1135-1139. PMID: 31970804.
    Citations:    
  4. Schwartzstein RM, Dienstag JL, King RW, Chang BS, Flanagan JG, Besche HC, Hoenig MP, Miloslavsky EM, Atkins KM, Puig A, Cockrill BA, Wittels KA, Dalrymple JL, Gooding H, Hirsh DA, Alexander EK, Fazio SB, Hundert EM. The Harvard Medical School Pathways Curriculum: Reimagining Developmentally Appropriate Medical Education for Contemporary Learners. Acad Med. 2020 Mar 03. PMID: 32134787.
    Citations:    
  5. Krupat E, Camargo CA, Espinola JA, Fleenor TJ, Strewler GJ, Dienstag JL. A snapshot of underrepresented physicians 15 years after medical school. Adv Health Sci Educ Theory Pract. 2020 Jan 25. PMID: 31982974.
    Citations:    
  6. Bloom PP, Mojtahed A, Bethea ED, Knooihuizen SA, Choi J, Dienstag JL, Chung RT, Hur C. Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. Dig Dis Sci. 2020 Jan; 65(1):312-321. PMID: 31363954.
    Citations:    
  7. Ufere NN, Donlan J, Waldman L, Patel A, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer J, Temel J, Chung RT, El-Jawahri A. Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. Liver Transpl. 2019 06; 25(6):859-869. PMID: 30963669.
    Citations:    
  8. Ufere NN, Donlan J, Waldman L, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer JA, Temel JS, Chung RT, El-Jawahri A. Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2592-2599. PMID: 30885884.
    Citations:    
  9. Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 10 01; 29(10):2085-2091. PMID: 30165371.
    Citations:    Fields:    
  10. Luther J, Dienstag JL. Reply to: "Primed for the spotlight: Transplantation for alcohol-associated liver disease". J Hepatol. 2018 07; 69(1):255. PMID: 29650334.
    Citations:    Fields:    
  11. Luther J, Dienstag JL. Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019 01; 17(1):A27. PMID: 29505903.
    Citations:    Fields:    
  12. Luther J, Dienstag JL. Reply to: "Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach". J Hepatol. 2018 06; 68(6):1323. PMID: 29505846.
    Citations:    Fields:    
  13. Kubiliun M, Patel SJ, Hur C, Dienstag JL, Luther J. Early liver transplantation for alcoholic hepatitis: Ready for primetime? J Hepatol. 2018 03; 68(3):380-382. PMID: 29175244.
    Citations: 1     Fields:    
  14. Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI. Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clin J Am Soc Nephrol. 2018 01 06; 13(1):16-25. PMID: 29122911.
    Citations: 1     Fields:    
  15. Krupat E, Pelletier SR, Dienstag JL. Academic Performance on First-Year Medical School Exams: How Well Does It Predict Later Performance on Knowledge-Based and Clinical Assessments? Teach Learn Med. 2017 Apr-Jun; 29(2):181-187. PMID: 28098483.
    Citations:    Fields:    Translation:Humans
  16. Krupat E, Camargo CA, Strewler GJ, Espinola JA, Fleenor TJ, Dienstag JL. Factors associated with physicians' choice of a career in research: a retrospective report 15 years after medical school graduation. Adv Health Sci Educ Theory Pract. 2017 Mar; 22(1):5-15. PMID: 27112959.
    Citations: 1     Fields:    Translation:Humans
  17. Krupat E, Dienstag JL, Kester WC, Finkelstein SN. Medical Students Who Pursue a Joint MD/MBA Degree: Who Are They and Where Are They Heading? Eval Health Prof. 2017 06; 40(2):203-218. PMID: 26801747.
    Citations: 1     Fields:    Translation:Humans
  18. Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL. Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials. 2014 May 07; 15:159. PMID: 24886378.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  19. Leape L, Shore M, Dienstag JL. In reply to Alexander et al. Acad Med. 2013 Jun; 88(6):741-2. PMID: 23708592.
    Citations:    Fields:    Translation:Humans
  20. Dienstag JL, Cosimi AB. Liver transplantation--a vision realized. N Engl J Med. 2012 Oct 18; 367(16):1483-5. PMID: 22992048.
    Citations: 11     Fields:    Translation:Humans
  21. Dienstag JL. The case for the new MCAT. N Engl J Med. 2012 07 19; 367(3):280-1; author reply 281-2. PMID: 22808979.
    Citations:    Fields:    Translation:Humans
  22. Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB. Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med. 2012 Jul; 87(7):845-52. PMID: 22622217.
    Citations: 27     Fields:    Translation:Humans
  23. Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB. Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med. 2012 Jul; 87(7):853-8. PMID: 22622219.
    Citations: 20     Fields:    Translation:Humans
  24. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Sep; 107(9):1388-98. PMID: 22688849.
    Citations: 3     Fields:    Translation:Humans
  25. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144. PMID: 22359532.
    Citations: 11     Fields:    Translation:Humans
  26. Dienstag JL. The Medical College Admission Test--toward a new balance. N Engl J Med. 2011 Nov 24; 365(21):1955-7. PMID: 22111717.
    Citations: 4     Fields:    
  27. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012 Apr; 32(4):665-74. PMID: 22103814.
    Citations: 5     Fields:    Translation:HumansCells
  28. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012 Jan; 107(1):64-74. PMID: 21931376.
    Citations: 27     Fields:    Translation:Humans
  29. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405. PMID: 21520194.
    Citations: 32     Fields:    Translation:Humans
  30. Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology. 2011 Sep; 141(3):900-908.e1-2. PMID: 21699796.
    Citations: 11     Fields:    Translation:Humans
  31. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8. PMID: 21480316.
    Citations: 13     Fields:    Translation:Humans
  32. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141(1):141-9. PMID: 21440548.
    Citations: 49     Fields:    Translation:Humans
  33. Dienstag JL. Evolution of the New Pathway curriculum at Harvard Medical School: the new integrated curriculum. Perspect Biol Med. 2011; 54(1):36-54. PMID: 21399382.
    Citations: 7     Fields:    Translation:Humans
  34. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci. 2011 Feb; 56(2):564-8. PMID: 21136163.
    Citations: 26     Fields:    Translation:Humans
  35. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140(3):840-9; quiz e12. PMID: 21129375.
    Citations: 73     Fields:    Translation:HumansCells
  36. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3):833-44. PMID: 20564351.
    Citations: 112     Fields:    Translation:Humans
  37. Dienstag JL, Neill JM. Harvard Medical School. Acad Med. 2010 Sep; 85(9 Suppl):S269-73. PMID: 20736566.
    Citations:    Fields:    
  38. Dienstag JL. Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye. Am J Gastroenterol. 2010 Aug; 105(8):1770-2. PMID: 20686463.
    Citations:    Fields:    Translation:Humans
  39. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9. PMID: 20675691.
    Citations: 27     Fields:    Translation:Humans
  40. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010 Oct; 8(10):877-83. PMID: 20362695.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  41. Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, So S. Recommendations for prevention, screening, and diagnosis of HBV and HCV infections. J Fam Pract. 2010 Apr; 59(4 Suppl):S29-35. PMID: 20398588.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  42. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010 Feb; 51(2):585-94. PMID: 20101752.
    Citations: 28     Fields:    Translation:Humans
  43. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010 Apr; 31(7):719-34. PMID: 20070284.
    Citations: 8     Fields:    Translation:Humans
  44. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009 Dec; 50(6):1738-49. PMID: 19824074.
    Citations: 20     Fields:    Translation:Humans
  45. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9. PMID: 19676128.
    Citations: 33     Fields:    Translation:Humans
  46. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb; 138(2):493-502. PMID: 19852963.
    Citations: 129     Fields:    Translation:Humans
  47. Bardes CL, Best PC, Kremer SJ, Dienstag JL. Perspective: Medical school admissions and noncognitive testing: some open questions. Acad Med. 2009 Oct; 84(10):1360-3. PMID: 19881422.
    Citations: 1     Fields:    Translation:Humans
  48. Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J, Twitchell K, Loomis SC, Abraczinskas DR, Terella AM, Dienstag JL, Chung RT. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol. 2009 Oct; 30(10):1000-5. PMID: 19743901.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  49. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010 Jan; 138(1):136-46. PMID: 19766643.
    Citations: 29     Fields:    Translation:Humans
  50. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec; 137(6):1986-94. PMID: 19747918.
    Citations: 9     Fields:    Translation:HumansCells
  51. Krupat E, Dienstag JL. Commentary: Assessment is an educational tool. Acad Med. 2009 May; 84(5):548-50. PMID: 19704183.
    Citations: 7     Fields:    Translation:Humans
  52. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009 May; 49(5 Suppl):S112-21. PMID: 19399795.
    Citations: 37     Fields:    Translation:HumansCells
  53. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 04; 359(23):2429-41. PMID: 19052125.
    Citations: 128     Fields:    Translation:HumansCells
  54. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26. PMID: 19068241.
    Citations: 14     Fields:    Translation:Humans
  55. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology. 2008 Nov; 48(5):1412-9. PMID: 18816437.
    Citations: 7     Fields:    Translation:HumansCells
  56. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008 Oct 02; 359(14):1486-500. PMID: 18832247.
    Citations: 245     Fields:    Translation:HumansCells
  57. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48. PMID: 18848939.
    Citations: 152     Fields:    Translation:Humans
  58. Dienstag JL. Relevance and rigor in premedical education. N Engl J Med. 2008 Jul 17; 359(3):221-4. PMID: 18635426.
    Citations: 7     Fields:    
  59. Dienstag JL. Hepatitis A: the vaccine dividend. J Infect Dis. 2008 May 01; 197(9):1220-2. PMID: 18422432.
    Citations:    Fields:    Translation:HumansCells
  60. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008 Mar; 47(3):789-98. PMID: 18175357.
    Citations: 41     Fields:    Translation:Humans
  61. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):234-41. PMID: 18237873.
    Citations: 11     Fields:    Translation:HumansCells
  62. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb; 47(2):605-12. PMID: 18157835.
    Citations: 49     Fields:    Translation:Humans
  63. Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008 Feb; 15(2):129-36. PMID: 18184196.
    Citations: 11     Fields:    Translation:Cells
  64. Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis. 2007 Nov; 11(4):851-68, ix. PMID: 17981232.
    Citations: 5     Fields:    Translation:HumansCells
  65. Dienstag J, Easley C, Kirkpatrick P. Telbivudine. Nat Rev Drug Discov. 2007 Apr; 6(4):267-8. PMID: 17458000.
    Citations: 6     Fields:    Translation:HumansCells
  66. Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig. 2007; 27(1):35-49. PMID: 17177578.
    Citations: 8     Fields:    Translation:Humans
  67. Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, Hall JG, Kwiatkowski RW, Wright T, Lai CL, Condreay LD. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat. 2007 Jan; 14(1):55-63. PMID: 17212645.
    Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
  68. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec; 44(6):1675-84. PMID: 17133499.
    Citations: 37     Fields:    Translation:Humans
  69. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31. PMID: 17196293.
    Citations: 35     Fields:    Translation:Humans
  70. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan; 132(1):103-12. PMID: 17241864.
    Citations: 54     Fields:    Translation:HumansCells
  71. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006 Aug; 44(2):360-7. PMID: 16871570.
    Citations: 14     Fields:    Translation:HumansCells
  72. Dienstag JL. Hepatitis C: a bitter harvest. Ann Intern Med. 2006 May 16; 144(10):770-1. PMID: 16702593.
    Citations: 5     Fields:    Translation:Humans
  73. Dienstag JL. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol. 2006; 101 Suppl 1:S19-25. PMID: 16448448.
    Citations: 1     Fields:    Translation:HumansCells
  74. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006 Jan; 130(1):231-64; quiz 214-7. PMID: 16401486.
    Citations: 83     Fields:    Translation:HumansPHPublic Health
  75. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006 Jan; 130(1):225-30. PMID: 16401485.
    Citations: 35     Fields:    Translation:Humans
  76. Wright TL, Avunduk C, Dienstag JL, Freston JW, Jacobson IM, Nord HJ, Sherman M. Advancing patient care: integrating new data. Am J Gastroenterol. 2006; 101 Suppl 1:S32-9. PMID: 16448450.
    Citations: 1     Fields:    Translation:Humans
  77. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005 Sep; 43(3):434-41. PMID: 16136646.
    Citations: 85     Fields:    Translation:HumansCTClinical Trials
  78. Di Giammarino L, Dienstag JL. Hepatitis A--the price of progress. N Engl J Med. 2005 Sep 01; 353(9):944-6. PMID: 16135841.
    Citations: 6     Fields:    Translation:HumansAnimalsPHPublic Health
  79. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug; 42(2):282-92. PMID: 15986415.
    Citations: 69     Fields:    Translation:Humans
  80. Dienstag JL. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol. 2005 Feb; 42(2):158-62. PMID: 15664237.
    Citations: 1     Fields:    Translation:Humans
  81. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct; 25(5):472-92. PMID: 15465617.
    Citations: 64     Fields:    Translation:HumansCTClinical Trials
  82. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr; 126(4):1015-23; discussion 947. PMID: 15057741.
    Citations: 99     Fields:    Translation:HumansCTClinical Trials
  83. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004 Mar; 2(3):266-72. PMID: 15017612.
    Citations: 19     Fields:    Translation:Humans
  84. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003 Dec; 125(6):1714-22. PMID: 14724824.
    Citations: 176     Fields:    Translation:HumansCellsCTClinical Trials
  85. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003 Jun; 38(6):818-26. PMID: 12763376.
    Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
  86. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003 Apr; 37(4):748-55. PMID: 12668966.
    Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
  87. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003 Mar 15; 36(6):687-96. PMID: 12627352.
    Citations: 153     Fields:    Translation:HumansCellsCTClinical Trials
  88. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17. PMID: 12512035.
    Citations: 143     Fields:    Translation:HumansCellsCTClinical Trials
  89. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002 Nov; 36(5 Suppl 1):S152-60. PMID: 12407589.
    Citations: 60     Fields:    Translation:Humans
  90. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002 Oct; 123(4):1061-9. PMID: 12360468.
    Citations: 201     Fields:    Translation:HumansCells
  91. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94. PMID: 12085364.
    Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
  92. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002 Mar; 35(3):688-93. PMID: 11870385.
    Citations: 25     Fields:    Translation:Humans
  93. Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection. Am J Gastroenterol. 2002 Feb; 97(2):478-83. PMID: 11866292.
    Citations: 11     Fields:    Translation:Humans
  94. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW, Burkhardt E. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001 Dec; 35(6):749-55. PMID: 11738102.
    Citations: 37     Fields:    Translation:HumansCTClinical Trials
  95. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, Albrecht JK, Dienstag JL. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat. 2001 Nov; 8(6):414-20. PMID: 11703572.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  96. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001 Mar; 33(3):751-7. PMID: 11230757.
    Citations: 75     Fields:    Translation:HumansCells
  97. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001 Feb; 33(2):424-32. PMID: 11172345.
    Citations: 46     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  98. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000 Nov; 119(5):1317-23. PMID: 11054390.
    Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
  99. Dienstag JL. Alternative therapy si, gene therapy no? Gastroenterology. 2000 Nov; 119(5):1189. PMID: 11054375.
    Citations:    Fields:    Translation:Humans
  100. Purcell RH, Alter HJ, Dienstag JL. Non-A, non-B hepatitis. 1976. Yale J Biol Med. 2000 Jan-Dec; 73(1-6):175-82. PMID: 11765936.
    Citations:    Fields:    Translation:HumansCells
  101. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis. 1999 Dec; 180(6):1757-62. PMID: 10558928.
    Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
  102. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999 Oct 21; 341(17):1256-63. PMID: 10528035.
    Citations: 230     Fields:    Translation:HumansCellsCTClinical Trials
  103. Dienstag JL, Schiff ER, Mitchell M, Casey DE, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology. 1999 Oct; 30(4):1082-7. PMID: 10498663.
    Citations: 23     Fields:    Translation:HumansCells
  104. Dienstag JL. New antiviral agents for viral hepatitis: our cup runneth over but is only half full. Gastroenterology. 1999 Sep; 117(3):525. PMID: 10464127.
    Citations:    Fields:    Translation:Humans
  105. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol. 1999 Aug; 58(4):353-8. PMID: 10421401.
    Citations: 19     Fields:    Translation:HumansCells
  106. Reid AE, Koziel MJ, Aiza I, Jeffers L, Reddy R, Schiff E, Lau JY, Dienstag JL, Liang TJ. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Am J Gastroenterol. 1999 Jun; 94(6):1619-26. PMID: 10364034.
    Citations: 4     Fields:    Translation:HumansCells
  107. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology. 1999 May; 29(5):1581-6. PMID: 10216146.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  108. Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation. 1998 Nov 15; 66(9):1254-8. PMID: 9825826.
    Citations: 21     Fields:    Translation:HumansCells
  109. Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, Houghton M, Walker BD, Koziel MJ. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol. 1998 Feb 01; 160(3):1479-88. PMID: 9570570.
    Citations: 38     Fields:    Translation:HumansCells
  110. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology. 1997 Sep; 26(3 Suppl 1):66S-70S. PMID: 9305667.
    Citations: 16     Fields:    Translation:Humans
  111. Dienstag JL. Management of chronic hepatitis C: a consensus. Gastroenterology. 1997 Aug; 113(2):375. PMID: 9247451.
    Citations: 1     Fields:    Translation:HumansCells
  112. Dienstag JL. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology. 1997 Feb; 112(2):651-5. PMID: 9024319.
    Citations: 5     Fields:    Translation:Humans
  113. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JY, Maertens G, Gogate J, Sanghvi B, Albrecht J. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology. 1996 Nov; 24(5):1034-40. PMID: 8903371.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  114. Harper SE, Dienstag JL. Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Hepatology. 1996 Apr; 23(4):930-3. PMID: 8666352.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  115. Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996 Apr; 84(4):812-20. PMID: 8638835.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  116. Johnson MW, Washburn WK, Freeman RB, FitzMaurice SE, Dienstag J, Basgoz N, Jenkins RL, Cosimi AB. Hepatitis C viral infection in liver transplantation. Arch Surg. 1996 Mar; 131(3):284-91. PMID: 8611094.
    Citations: 2     Fields:    Translation:Humans
  117. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995 Dec 21; 333(25):1657-61. PMID: 7477217.
    Citations: 119     Fields:    Translation:HumansCellsCTClinical Trials
  118. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant. 1995 Dec; 9(6):463-71. PMID: 8645890.
    Citations: 21     Fields:    Translation:Humans
  119. Katkov WN, Dienstag JL. Hepatitis vaccines. Gastroenterol Clin North Am. 1995 Mar; 24(1):147-59. PMID: 7729858.
    Citations: 1     Fields:    Translation:Humans
  120. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis. 1995 Feb; 15(1):101-9. PMID: 7597440.
    Citations: 4     Fields:    Translation:HumansCells
  121. Rall CJ, Dienstag JL. Epidemiology of hepatitis C virus infection. Semin Gastrointest Dis. 1995 Jan; 6(1):3-12. PMID: 7894965.
    Citations: 2     Fields:    Translation:Humans
  122. Eason JD, Freeman RB, Rohrer RJ, Lewis WD, Jenkins R, Dienstag J, Cosimi AB. Should liver transplantation be performed for patients with hepatitis B? Transplantation. 1994 Jun 15; 57(11):1588-93. PMID: 8009592.
    Citations: 4     Fields:    Translation:HumansCells
  123. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther. 1994 Mar-Apr; 16(2):334-43; discussion 271-2. PMID: 8062327.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  124. Liang TJ, Hasegawa K, Munoz SJ, Shapiro CN, Yoffe B, McMahon BJ, Feng C, Bei H, Alter MJ, Dienstag JL. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest. 1994 Feb; 93(2):550-5. PMID: 8113393.
    Citations: 15     Fields:    Translation:HumansCells
  125. Katkov WN, Watkins E, DeMelia HC, Dienstag JL. Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults. J Viral Hepat. 1994; 1(1):79-83. PMID: 8790563.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  126. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W, et al. Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. J Viral Hepat. 1994; 1(1):55-63. PMID: 8790560.
    Citations: 6     Fields: